LAUSR

ABSTRACT Introduction: Several studies have evaluated the association between the multidrug resistance 1 (MDR1) polymorphism (rs1045642 C > T) and multiple myeloma (MM). However, the results were not consistent. Therefore, to reach a comprehensive and reliable answer we determined the association of the MDR1 (rs1045642 C > T) polymorphism and MM in the context of meta-analysis. Methods: All eligible studies published in EMBASE, PubMed, and Web of Science databases before July 2017 were reviewed. Subsequently, to assess the strength of association in the dominant model, recessive model, allelic model, homozygotes contrast, and heterozygotes contrast, pooled odds ratios and 95% confidence intervals (CIs) were calculated by the fixed effects model. Results: A total of four case–control studies with 395 MM cases and 418 healthy controls were included in the meta-analysis. The overall results showed no significant association between the MDR1 (rs1045642 C > T) polymorphism and the risk of MM in genetic models (dominant model: OR = 1.04, 95% CI = 0.78–1.38; recessive model: OR = 0.74, 95% CI = 0.52–1.06; allelic model: OR = 0.90, 95% CI = 0.73–1.11; TT vs. CC: OR = 0.80, 95% CI = 0.51–1.25; and CT vs. CC: OR = 1.12, 95% CI = 0.77–1.62). No evidence of publication bias was detected except for the analysis of the recessive model. Conclusion: This meta-analysis suggests that the MDR1 C > T polymorphism was not associated with the risk of MM. To confirm these findings, further comprehensive and well-designed studies are needed.